Anidulafungin In Treatment Of Candidemia In Asian Subjects

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (876 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: hourssubjectsmultiple48to determine
  Phrases that lowered it: efficacy andand safetysafety ofinfectionblood
• Sponsor's past termination rate: 13.8% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 7.7% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: not given (raises risk) · Design
• Sponsor's past trials: 348 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 244 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 88.5% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Disease area, infectious disease: Yes (lowers risk) · Disease area
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis NCT01176058 · started 2010 · scored riskier than 40% of active trials terminated
• Anidulafungin in Patients With Hematologic Malignancies NCT01053884 · started 2009 · scored riskier than 45% of active trials terminated
• An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System NCT00806351 · started 2009 · scored riskier than 58% of active trials terminated
• An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia NCT03604705 · started 2018 · scored riskier than 42% of active trials completed
• CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension NCT02734862 · started 2016 · scored riskier than 47% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.